Katz Laurence Y, Kozyrskyj Anita L, Prior Heather J, Enns Murray W, Cox Brian J, Sareen Jitender
Department of Psychiatry, University of Manitoba, Winnipeg, Man.
CMAJ. 2008 Apr 8;178(8):1005-11. doi: 10.1503/cmaj.071265.
Regulatory bodies worldwide, including Health Canada, have issued warnings about prescribing antidepressants to children and adolescents. We sought to determine whether the Health Canada warning had the desired effects on prescribing patterns and outcomes and whether it had any unintended health consequences.
We examined data from prescription and health care databases representing more than 265 000 children, adolescents and young adults annually to determine changes in the rates of antidepressant prescription, use of health services and outcomes in these populations in the 9 years before and the 2 years after the Health Canada warning. We also examined the data for unintended changes in these rates among patients with anxiety disorders. We used young adults as the comparison group because they were not targeted by the warning.
Following the warning, the rate of antidepressant prescriptions decreased among children and adolescents (relative risk [RR] 0.86, 95% confidence interval [CI] 0.81-0.91) and among young adults (RR 0.90, 95% CI 0.86-0.93). Ambulatory visits because of depression decreased among children and adolescents (RR 0.90, 95% CI 0.85-0.96) and young adults (RR 0.91, 95% CI 0.87-0.96). The rate of completed suicides among children and adolescents rose significantly after the warning (RR 1.25, 95% CI 1.08-1.44; annual rate per 1000 = 0.04 before and 0.15 after the warning). There was no equivalent change in the rate of completed suicides among young adults (RR 1.01, 95% CI 0.93-1.10; annual rate per 1000 = 0.15 before and 0.22 after the warning). Among patients with an anxiety disorder, the prescription rates did not change among children and adolescents, except for a decrease in the use of selective serotonin reuptake inhibitors other than fluoxetine, but the rates among young adults changed similar to the pattern of changes in the overall prescribing of antidepressants. There was also a significant decrease in the rate of physician visits because of anxiety disorders among young adults after the warning.
Health advisories and warnings issued by regulatory bodies may have unintended consequences on the provision of care, delivery of health services and clinical outcomes. Further efforts are required to ensure that health warnings do not result in unexpected harm.
包括加拿大卫生部在内的全球监管机构已就给儿童和青少年开具抗抑郁药发出警告。我们试图确定加拿大卫生部的警告是否对处方模式和结果产生了预期效果,以及是否产生了任何意外的健康后果。
我们研究了来自处方和医疗保健数据库的数据,这些数据每年代表超过26.5万名儿童、青少年和青年,以确定在加拿大卫生部发出警告前9年和发出警告后2年这些人群中抗抑郁药处方率、医疗服务使用情况和结果的变化。我们还研究了焦虑症患者这些比率的意外变化数据。我们将青年作为对照组,因为警告并未针对他们。
警告发出后,儿童和青少年(相对风险[RR]0.86,95%置信区间[CI]0.81 - 0.91)以及青年(RR 0.90,95% CI 0.86 - 0.93)的抗抑郁药处方率均下降。因抑郁症进行的门诊就诊在儿童和青少年(RR 0.90,95% CI 0.85 - 0.96)以及青年(RR 0.91,95% CI 0.87 - 0.96)中均减少。警告发出后,儿童和青少年的自杀完成率显著上升(RR 1.25,95% CI 1.08 - 1.44;警告前每1000人的年率为0.04,警告后为0.15)。青年的自杀完成率没有类似变化(RR 1.01,95% CI 0.93 - 1.10;警告前每1000人的年率为0.15,警告后为0.22)。在焦虑症患者中,儿童和青少年的处方率没有变化,除了氟西汀以外的选择性5-羟色胺再摄取抑制剂的使用有所减少,但青年中的比率变化与抗抑郁药总体处方的变化模式相似。警告发出后,青年因焦虑症进行的医生就诊率也显著下降。
监管机构发布的健康建议和警告可能会对医疗护理的提供、医疗服务的提供和临床结果产生意外后果。需要进一步努力确保健康警告不会导致意外伤害。